PAR 5.77% 24.5¢ paradigm biopharmaceuticals limited..

100% agree. PR is doing both PAR and NSB a disservice by acting...

  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    100% agree. PR is doing both PAR and NSB a disservice by acting as a part-time CEO to both, and both have suffered tremendously as a result. I have therefore changed my sentiment to sell until I hear that PR has resigned from either NSB or PAR or both. I have no issue with PR acting as a consultant to NSB, but he is stretched far too thin IMO.

    There is so much our CEO could be doing for PAR, but isn't. To put things into perspective, PR gets paid way more than Albo, but only does a fraction of the work.

    My views only, dyor.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.